We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

70 hedge funds and large institutions have $103M invested in Protagonist Therapeutics in 2018 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

107% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 15

36% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 14

6% more funds holding

Funds holding: 66 → 70 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.23% less ownership

Funds ownership: 57.79% → 56.56% (-1.2%)

55% less capital invested

Capital invested by funds: $226M → $103M (-$123M)

Holders
70
Holders Change
+4
Holders Change %
+6.06%
% of All Funds
1.6%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
19
Increased
31
Reduced
15
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
+$20.4M
2
BlackRock
BlackRock
New York
+$3.63M
3
American Century Companies
American Century Companies
Missouri
+$2.69M
4
TCM
Tekla Capital Management
Massachusetts
+$2.57M
5
OAM
Oxford Asset Management
United Kingdom
+$2.49M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$19.9M
2
EAM
Eventide Asset Management
Massachusetts
-$5.72M
3
First Manhattan
First Manhattan
New York
-$5.12M
4
DM
Deerfield Management
New York
-$4.68M
5
JP Morgan Chase
JP Morgan Chase
New York
-$3.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$27.2M +$1.76M +93,617 +3%
EC
2
EcoR1 Capital
California
$9.31M +$20.4M +1,083,567 New
FCM
3
Farallon Capital Management
California
$8.71M +$2.14M +113,500 +13%
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$8.59M -$19.9M -1,056,076 -51%
PI
5
Pharmstandard International
Luxembourg
$8.44M – – –
BlackRock
6
BlackRock
New York
$5.9M +$3.63M +192,632 +39%
Vanguard Group
7
Vanguard Group
Pennsylvania
$4.51M +$789K +41,913 +9%
BI
8
BVF Inc
California
$3.48M +$2.1M +111,483 +38%
CAM
9
Cormorant Asset Management
Massachusetts
$3.28M -$336K -17,861 -4%
Millennium Management
10
Millennium Management
New York
$2.75M +$2.41M +128,009 +66%
TCM
11
Tekla Capital Management
Massachusetts
$1.88M +$2.57M +136,220 +164%
SAM
12
Senzar Asset Management
New York
$1.51M -$75.5K -4,010 -2%
OAM
13
Oxford Asset Management
United Kingdom
$1.42M +$2.49M +132,304 +397%
State Street
14
State Street
Massachusetts
$1.31M +$304K +16,138 +12%
First Manhattan
15
First Manhattan
New York
$1.24M -$5.12M -271,920 -65%
American Century Companies
16
American Century Companies
Missouri
$1.23M +$2.69M +142,834 New
Geode Capital Management
17
Geode Capital Management
Massachusetts
$1.22M +$32.1K +1,707 +1%
Northern Trust
18
Northern Trust
Illinois
$1.09M -$3.39K -180 -0.1%
SIM
19
Spark Investment Management
New York
$701K +$1.13M +60,200 +280%
TCIM
20
TIAA CREF Investment Management
New York
$658K +$831K +44,106 +136%
Federated Hermes
21
Federated Hermes
Pennsylvania
$549K +$876K +46,496 +267%
Acadian Asset Management
22
Acadian Asset Management
Massachusetts
$498K +$914K +48,522 +513%
Invesco
23
Invesco
Georgia
$484K +$1.06M +56,308 New
Renaissance Technologies
24
Renaissance Technologies
New York
$448K +$983K +52,200 New
Bank of New York Mellon
25
Bank of New York Mellon
New York
$430K +$103K +5,493 +12%
1
2 3 4

PTGX Hedge Fund Activity: Q1 2018 in Review

70 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q1 2018, worth a combined $103M — down 55% from $226M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new PTGX positions and 14 closed out — a net gain of 5 holders — while 31 added to existing stakes and 15 trimmed.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $20.4M. The largest seller was Adage Capital Partners, cutting an estimated $19.9M.

  • 70 institutional investors held Protagonist Therapeutics (PTGX) as of Q1 2018, up from 66 in Q4 2017.
  • Funds reported $103M of Protagonist Therapeutics stock for Q1 2018, down 55% quarter-over-quarter.
  • 19 funds opened new Protagonist Therapeutics positions in Q1 2018 and 14 closed out, a net change of +5 holders.
  • The largest Protagonist Therapeutics buyer in Q1 2018 was EcoR1 Capital, an estimated $20.4M added.
  • The largest Protagonist Therapeutics seller in Q1 2018 was Adage Capital Partners, an estimated $19.9M sold.

Based on aggregated 13F filings for Q1 2018.